Skip to main content

Treatment Clinical Trials for Cervical Cancer

Review the cervical cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 51-75 of 94

Cisplatin-based Hypofractionated Radiation Therapy followed by Brachytherapy in Treating Patients with Bulky or Metastatic Cervical Cancer
Status: Active
Location: University of Kentucky/Markey Cancer Center, Lexington, Kentucky
Pembrolizumab and Lenvatinib for the Treatment of Patients with Metastatic and Recurrent Cervical Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Stereotactic Body Radiation Therapy and Atezolizumab in Treating Patients with Recurrent, Persistent, or Metastatic Cervical, Vaginal, or Vulvar Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
External Beam Radiation Therapy and Brachytherapy with Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
Status: Active
Location: 5 locations
Radiation Therapy (ABC-RT) for the Treatment of Patients with Stage IB3-IVA Cervical Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Study of NEO-201 in Solid Tumors Expansion Cohorts
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Single Protein Encapsulated Doxorubicin for the Treatment of Advanced, Refractory or Relapsed Solid Tumor Malignancies
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Genetically Engineered Tumor Infiltrating Lymphocytes (KSQ-004EX) for the Treatment of Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Hypofractionated Radiation Therapy with Adaptive Planning for the Treatment of Endometrial and Cervical Cancer, HERA Trial
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Fenofibrate for the Treatment of Patients with Cervical Dysplasia or Invasive Cervical Cancer
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
A Theranostic Approach ([68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G) for the Detection and Treatment of Metastatic Cancers
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
KK-LC-1 TCR T Cells for the Treatment of Metastatic Gastric, Lung, Breast, and Cervical Cancers
Status: Active
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Cancer Patients
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
E7 TCR-T Cell Induction Therapy for the Treatment of Locoregionally Advanced HPV-Associated Cancers
Status: Active
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Status: Active
Location: Northwestern University, Chicago, Illinois
Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pomalidomide and Nivolumab for the Treatment of Virus-Associated Malignancies with or without HIV
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma